Ark Clinical Research Launches Mobile Unit to Enhance Decentralized Clinical Trials and Diversity
Key Insights
Ark Clinical Research (search) is launching a mobile unit in early 2025 to broaden the reach of clinical trials, focusing on engaging diverse populations and enhancing accessibility.
The mobile unit supports decentralized clinical trials (DCTs) by enabling remote procedures like blood draws and sample collections, reducing participant burden and improving engagement.
This initiative aims to strengthen community ties, build trust, and improve the quality and relevance of clinical trial data by ensuring broader representation across various demographics.
Ark Clinical Research (search) is set to launch a mobile unit in early 2025, marking a significant step towards decentralized clinical trials (DCTs) and enhanced diversity in research. This initiative aims to bring clinical trials directly to participants, particularly those in underserved communities, thereby increasing accessibility and ensuring broader representation in clinical research.
Enhancing Accessibility and Decentralized Trials
Historically, clinical trials have been limited by geographic constraints, often excluding rural populations, minorities, and lower-income groups. Ark's mobile unit addresses this issue by bringing trial-related activities to convenient locations for participants. This approach aligns with the growing trend of DCTs, which allow trial activities to occur remotely, including telehealth visits and in-home visits.
"The launch of our mobile unit is a transformative step in improving accessibility," said Samira Moran, CEO & President of Ark Clinical Research (search). "It allows us to reach diverse populations, ensuring our trials are more inclusive and representative of the population of patients who need medical care."
The mobile unit will facilitate key trial procedures such as blood draws, sample collections, and patient monitoring remotely. This is particularly beneficial for Ark's work in metabolic disorders (search), central nervous system (CNS (search)) conditions, and vaccine development, where frequent visits can be a barrier to participation. The FDA has also provided guidance on conducting DCTs, further supporting this modernization of trial operations.
Strengthening Community Engagement and Data Quality
Beyond accessibility, the mobile unit will strengthen Ark’s ties with local communities, building trust and engagement, especially in communities historically wary of clinical trials. The unit will conduct community outreach events, health screenings, and educational initiatives to inform individuals about clinical research and encourage participation. Collaborations with local healthcare providers will further reinforce Ark's commitment to improving public health.
By reaching a more diverse participant base, Ark aims to enhance the quality and applicability of clinical trial data. Broader representation across ethnicity, socioeconomics, and geography will ensure that findings are relevant to a wider array of individuals, leading to more comprehensive and effective treatments. Strict adherence to protocols and the use of digital health technologies will ensure the accuracy, consistency, and reliability of the collected data.
Ark’s mobile unit represents a significant advancement in making clinical trials more accessible, inclusive, and representative. By embracing mobility and decentralization, Ark is poised to lead the industry in forward-thinking clinical trial design, ensuring that cutting-edge research benefits patients in need.